Publications & Presentations

Filter by Category:

Mechanistic Characterization of Azetukalner: KV7 Binding, Enhanced Channel Opening, and Rational Polytherapy Potential in Epilepsy

Congress: European Epilepsy Congress (September 6, 2026)
Authors: Sankar R, et al.

Tags

Azetukalner in Epilepsy

Long-Term Safety and Efficacy of Azetukalner, a Novel, Potent KV7 Potassium Channel Opener, in Adults With Focal Epilepsy: ≥48-Month Interim Analysis of the Ongoing 7-Year X-TOLE Open-Label Extension

Congress: European Epilepsy Congress (September 6, 2026)
Authors: French JA, et al.
Encore of AES 2025

Tags

Azetukalner in Epilepsy

Characterization of Long-Term Seizure Freedom in the Ongoing Open-Label Extension of X-TOLE: Potential Implications for Future Clinical Practice

Congress: European Epilepsy Congress (September 6, 2026)
Authors: Becker DA, et al.
Encore of AES 2025

Tags

Azetukalner in Epilepsy

Clinical Practice and Patient Burden Associated With Antiseizure Medication Titration: A Thematic Analysis

Congress: European Epilepsy Congress (September 6, 2026)
Authors: Stern JM, et al.
Encore of AES 2025

Tags

Epilepsy Real World Studies

Selective Potentiation of NaV1.1 Channels by Small-Molecule XPC-837 in Dravet Mice Suppresses Spontaneous Seizures, Prevents SUDEP, Increases Long-Term Potentiation, and Normalizes Gene Expression

Congress: European Epilepsy Congress (September 6, 2026)
Authors: Goodchild SJ, et al.
Encore of AAN 2026

Tags

Early-Stage Programs

Results from the Phase 3 X-TOLE2 Study Evaluating Azetukalner, a Novel, Potent KV7 Channel Opener, in Adults With Focal Onset Seizures (FOS)

Congress: 2026 Annual Meeting of the American Academy of Neurology (AAN) (April 19, 2026)
Authors: French, JA et al.

Tags

Azetukalner in Epilepsy

Treatment Experiences with Anti-seizure Medications (ASMs): Patient–Clinician Perspectives on Titration Burden, Quality of Life, and No‑Titration Options

Congress: 2026 Annual Meeting of the American Academy of Neurology (AAN) (April 19, 2026)
Authors: Stern, JM et al.

Tags

Azetukalner in Epilepsy

Multivariable Models Reporting Increased Economic and Humanistic Burden Among Patients With Epilepsy Reporting Focal Seizures (FS) Experiencing Moderate to Severe Depression Symptoms

Congress: American Epilepsy Society Annual Meeting (December 7, 2025)
Authors: Ong, A et al.

Tags

Epilepsy Real World Studies

Depression Symptom Experience Among Patients with Epilepsy Reporting a Diagnosis of Focal Seizures (FS): A Patient-Reported Outcomes Study

Congress: American Epilepsy Society Annual Meeting (December 6, 2025)
Authors: Wagner, JM, et al

Tags

Epilepsy Real World Studies

Impact of Depression on Outcomes and Treatment Patterns in Patients with Newly Diagnosed Epilepsy: A Retrospective Claims Analysis

Congress: American Epilepsy Society Annual Meeting (December 6, 2025)
Authors: Terman S, et al.

Tags

Epilepsy Real World Studies

Azetukalner, a Novel Kv7 Potassium Channel Opener, in Adults with Major Depressive Disorder: A Randomized Clinical Trial

Source: JAMA Network Open
Authors: Butterfield NN et al.
Published online May 27, 2025

Tags

Azetukalner in Depression

Interim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults with focal epilepsy

Source: Epilepsia Open
Authors: French JA, Porter RJ, Perucca E, Brodie MJ, Rogawski MA, Harden C, et al.
Published online March 7, 2025

Tags

Azetukalner in Epilepsy

Efficacy and Safety of XEN1101, a Novel Potassium Channel Opener, in Adults With Focal Epilepsy: A Phase 2b Randomized Clinical Trial

Source: JAMA Neurology
Authors: French JA, Porter RJ, Perucca E, et al.
Published online October 09, 2023

Tags

Azetukalner in Epilepsy

Investors

Investor inquiries

Email alerts